- Home
- ENTX vs RCON Comparison
ENTX vs RCON Comparison
Compare ENTX & RCON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- RCON
- Stock Information
- Founded
- ENTX 2010
- RCON 2007
- Country
- ENTX Israel
- RCON China
- Employees
- ENTX N/A
- RCON N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- RCON Oilfield Services/Equipment
- Sector
- ENTX Health Care
- RCON Energy
- Exchange
- ENTX Nasdaq
- RCON Nasdaq
- Market Cap
- ENTX 82.2M
- RCON 86.1M
- IPO Year
- ENTX 2018
- RCON 2009
- Fundamental
- Price
- ENTX $1.83
- RCON $2.13
- Analyst Decision
- ENTX Strong Buy
- RCON
- Analyst Count
- ENTX 1
- RCON 0
- Target Price
- ENTX $10.00
- RCON N/A
- AVG Volume (30 Days)
- ENTX 77.0K
- RCON 70.6K
- Earning Date
- ENTX 11-07-2025
- RCON 09-26-2025
- Dividend Yield
- ENTX N/A
- RCON N/A
- EPS Growth
- ENTX N/A
- RCON N/A
- EPS
- ENTX N/A
- RCON N/A
- Revenue
- ENTX $166,000.00
- RCON $8,996,572.00
- Revenue This Year
- ENTX N/A
- RCON N/A
- Revenue Next Year
- ENTX N/A
- RCON $12.17
- P/E Ratio
- ENTX N/A
- RCON N/A
- Revenue Growth
- ENTX 191.23
- RCON N/A
- 52 Week Low
- ENTX $1.50
- RCON $1.40
- 52 Week High
- ENTX $2.79
- RCON $7.16
- Technical
- Relative Strength Index (RSI)
- ENTX 41.92
- RCON 44.74
- Support Level
- ENTX $1.83
- RCON $1.87
- Resistance Level
- ENTX $2.22
- RCON $2.13
- Average True Range (ATR)
- ENTX 0.11
- RCON 0.19
- MACD
- ENTX -0.02
- RCON 0.01
- Stochastic Oscillator
- ENTX 7.14
- RCON 46.55
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About RCON Recon Technology Ltd.
Recon Technology Ltd is an oilfield service company. The company is engaged in providing oilfield automation products, specialized equipment for oil and gas production and transportation, chemicals, and field services to petroleum companies mainly in the People's Republic of China (PRC). It has four reportable operating segments: Automation Product and Software, Equipment and Accessories, Platform outsourcing services, and Oilfield Environmental Protection. The majority of the firm's revenue comes from the Automation Product and Software segment which provides products and services like pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system among others.